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Background: When evaluating the outcomes of treatment in paediatric endocrinology, the health-related quality of
life (HrQoL) of the child is to be taken into consideration. Since few self–reported HrQoL instruments exist for
children with diagnosed short stature (dSS), the objective of this study was to develop and psychometrically test a
targeted HrQoL instrument for use in multinational clinical research.
Methods: The target population were short stature (height < −2 SDS) children and adolescents (age 8–12 and
13–18 years) with a diagnosis of growth hormone deficiency (GHD) or idiopathic short stature (ISS), differing in
growth hormone treatment status. Focus group discussions for concept and item generation, piloting of the
questionnaire with cognitive debriefing, and instrument field testing with a retest were conducted simultaneously
in five countries. After qualitative and preliminary quantitative analyses, psychometric testing of field test data in
terms of reliability and validity including confirmatory factor analyses (CFA) was performed.
Results: Following item generation from focus group discussions, 124 items were included in a pilot test with a
cognitive debriefing exercise providing preliminary feedback on item and domain operating characteristics. A field
test with 268 participants showed high internal consistency reliabilities (alpha 0.82 – 0.95), good correlations with
generic measures (up to r = .58), significant known group differences (e.g. in height: F = 32, df 244, p < 0.001) and
an acceptable CFA model fit suggesting construct validity of the three-domain core structure with 22 items,
supplemented by three mediator domains with 28 items.
Conclusions: The QoLISSY questionnaire is a promising step forward in assessing the impact of dSS on HrQoL. It is
based on items generated from the subjective experience of short stature children referred for endocrine
investigation, is validated for use in five languages and it is easy to administer in clinical and research settings.
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Health-related quality of life (HrQoL) is increasingly seen
as an important outcome in clinical medicine. HrQoL in-
cludes subjective physical, emotional and social aspects of
well-being and functioning from the patient’s perspective
and extends to the perspective of other persons [1,2]. To
understand the effects of a health condition on well-being
and functioning in paediatric medicine, it is important to
capture the view of the young patients and their parents.
Very few instruments have been developed in the area of
paediatric endocrinology, and assessments of well-being
and functioning from the perspectives of children and ad-
olescents are needed. Specifically, there is a lack of vali-
dated instruments to assess HrQoL in children and
adolescents diagnosed with short stature (dSS) [3-6].
In two recent literature reviews, measures to assess
HrQoL in dSS were identified; however, it was found that
none were aimed at dSS as an isolated characteristic, only
a few were self-reported and none specifically considered
the HrQoL of dSS children with idiopathic short stature
(ISS) [2,7]. Furthermore, most measures were developed
for use within a single language population, so that
pooling data across several countries could not be under-
taken and comparison of the HrQoL impact of dSS across
countries is not possible [8]. As a result of the paucity of
instruments few studies have examined the effect of
growth hormone (GH) treatment on HrQoL in short chil-
dren and adolescents [9-14]. Stephen et al. [15] is one of
the few papers which examined HrQoL in treated and un-
treated children with dSS using a generic instrument
(PedsQL). The results suggest that some differences be-
tween dSS and normal height children exist, but the meas-
ure was not designed to include the specific problems of
short stature children and therefore may be unable to de-
tect differences between treated and untreated children.
The aim of the work presented here was to develop a
methodologically sound condition specific HrQoL instru-
ment for dSS, which is conceptually appropriate for a
health-referral population, can be completed from both
the child and parent perspectives and is available in several
languages. This instrument was planned to be applicable
in a wide range of research and clinical contexts, ranging
from observational studies regarding the burden of dSS to
randomized clinical trials examining treatment effects. In
view of the need for a multi-language measure, instrument
development and testing were performed simultaneously
in five European countries (France, Germany, Spain,
Sweden and the UK). Additional validation is on-going in
other countries and languages.
In general, dSS is defined statistically in reference to the
average height for a person's age, sex and is best expressed
as a standard deviation score (SDS) away from the average
for the comparison population. The definition of dSS there-
fore depends on representative population data which iscollected on a national level. In general, a height SDS
below −2 is considered to be short, may be an indication of
an underlying, known or unknown, medical condition, and
would be referred for assessment by an endocrine clinic. By
using SDS in relation to parental heights instead of height
in cm it is possible to make comparisons across genetic
dispositions, age groups and gender [16,17]. Sex-specific
reference data for height have been published for most de-
veloped countries and ethnic sub-populations thus allowing
an auxological assessment of the child and the family to be
used to identify dSS early in childhood.
Factors regulating somatic growth have been intensively
researched and can be differentiated with regard to gen-
etic, pathophysiological and environmental factors. Short
stature may be associated with a number of health condi-
tions such as prolonged hormone deficiency, systemic dis-
ease (e.g. chronic kidney disease, chronic inflammation),
chromosomal abnormalities, inherited diseases, birth de-
fect syndromes or may not be attributable to any specific
cause (idiopathic short stature [ISS]) [18].
For children whose height is substantially below the
norm for age and gender, short stature as an isolated char-
acteristic may constitute a risk factor for behavioural and
emotional problems. This is not only because of barriers
in everyday life caused by height-related physical limita-
tions, but also because short stature can be regarded as a
social stigma, which in turn may affect self-perception
and the social integration of persons with short stature.
The intensity of impairment depends not only on the de-
gree of short stature, but also on the way the individuals
perceive their height and their ability to cope with the
stigma [19-22].
Short stature, as a medical condition, can be ascertained
early in life and depending on the underlying diagnosis it
can be treated with GH therapy from an early age in child-
hood. Growth hormone deficiency (GHD) as one of the
endocrine causes of short stature is the principle indicator
for GH treatment [23]. However, although treatment with
GH is also approved in other, non-GHD conditions where
dSS is a symptom such as in Turner syndrome or ISS, reg-
ulations regarding which conditions are approved for GH
treatment can differ between countries [24,25].
The most common growth related conditions presented
at a growth clinic are GHD and ISS. The majority of chil-
dren with identified GHD are treated with GH [26-28]. In
contrast, although the clinical effectiveness of GH treat-
ment in ISS is well documented [27,29,30] it is seldom
treated even in countries where it is an approved condi-
tion [31]. In Europe, treatment of ISS with GH is not ap-
proved by the European Medicines Agency [25], whereas
in the United States this indication has been approved
since 2003.
The primary aim of GH treatment in children with dSS
is to substitute the GH needed for normal development
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the expectation that this will also increase well-being and
functioning [32]. An association between height and
HrQoL has been documented in adults in the UK [33].
However, the treatment effect on children’s and adoles-
cents’ HrQoL has not been similarly documented.
So far, studies have addressed the parent perspective on
dSS more frequently than the perspective of the young pa-
tients themselves. Consequently more is known about
how parents view the impact of dSS on their children,
themselves, and their families [34-37].
The psychological aspects of dSS have been discussed
in the literature for a number of years, starting with earl-
ier publications about the impact of dSS on psycho-
logical functioning and the role of adaptation. However,
past research has not explicitly considered the effect of
dSS as an isolated characteristic in the broader context
of well-being and HrQoL [38-42].
The current study aimed to develop an instrument to
assess HrQoL in children and adolescents with short stat-
ure referred to a specialized growth center.
Since the main focus was on diagnosed short stature as
an isolated characteristic, short children with other med-
ical conditions potentially affecting HrQoL were excluded,
as these conditions are frequently associated with dys-
morphic features, pronounced comorbidities or develop-
mental delays (such as in Turner syndrome, Prader-Willi
syndrome, or in children born small for gestational age).
The main objective of this paper is to describe the op-
erating characteristics and psychometric performance of
the Quality of Life in Short Stature Youth (QoLISSY)
measure in children and adolescents. The results of the
development of the parent version will be reported sep-
arately as will be the detailed cross-cultural analysis of
child and parent versions.Methods
The development of the QoLISSY instrument was carried
out in three stages, conducted simultaneously in the five
countries according to standardized guidelines, [43,44]:
 identification of relevant HrQoL concepts,
dimensions and items in focus groups,
 pilot testing and cognitive debriefing of the
preliminary questionnaire and
 analysis of psychometric properties of the
instrument in a field test with a retest.
The study was reviewed and approved by the relevant
ethics committees at the centers as required by national
or regional regulation. All development stages were car-
ried out in each participating country: France, Germany,
Spain, Sweden and the United Kingdom.In each of the collaborating countries HrQoL re-
searchers worked with paediatric endocrinologists who
recruited patients and parents for inclusion in the study.
In order to capture the views of those concerned, the
focus on short stature youth was limited to families in-
volved in health care utilization. Based on medical records,
patients between the ages of 8 and 18 who were (or had
been before treatment) 2.0 standard deviations (SD) or
more below the mean for height in that country because
of GHD or ISS were eligible to participate. Children were
recruited independent of treatment status; i.e. being treat-
ment naïve, currently being treated or having had prior
but not current treatment. Parents were also included in
the study and respective results will be reported in a separ-
ate paper.
Focus groups
Patient inclusion was conducted through endocrinology
centers in the respective countries. Centers identified
potential participant families based on clinic records and
solicited their participation by mail which included in-
formation about the study along with a consent form.
The composition of focus groups was determined by age
(8–12, 13–18 years).
The focus group discussion was based on a semi-
structured interview developed in prior international
paediatric HrQoL research [45]. It was moderated by a
trained interviewer and an assistant, who asked questions
beginning with life in general and then focused on well-
being and functioning with dSS. All discussions were
audio-taped and transcribed into the local language.
The transcripts were screened by the researchers and
relevant verbatim statements were abstracted, taking
care to retain the wording used by the focus group sub-
jects. Each statement was annotated with an identifica-
tion of age, gender, diagnosis, treatment status and
country. Analysis of the statements was carried out in a
consensus group meeting of the project investigators. All
statements were copied onto individual cards in both
their original language and in a translation to English
conducted by bilingual (local and English) study center
personnel. The use of English as a core language reflects
the need to have a mechanism by which all investigators
could evaluate and sort the statements into concepts.
The content analysis was conducted via a card sorting
procedure. The first stage was to separate the generic
HrQoL statements from specific growth related HrQoL
statements, the specific statements were sorted into con-
ceptually similar areas and thematically labeled thus pro-
viding collections of statements reflecting the same
theme in different languages. This process then was cross-
checked by other groups so that the representativeness of
the categories found was validated within the process. The
statements were sorted into the dimensional models and
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items that were relevant in terms of content. Each state-
ment sub-domain was discussed in the expert group to
determine the core statements which uniquely reflected
the concepts. A decision was then made about the word-
ing and structure of the response categories so that a
self-reported, pen and paper questionnaire for children 8
to 18 years of age was available for pilot testing. In
addition, the conceptual model developed as a result of
the focus group categorization process led to the differ-
entiation between HrQoL domains and their potential
determinants.
The pilot questionnaire was assembled in English, and
items as well as the response scales were back-translated
into the respective languages by native speakers bilingual
in English. The translated version was reconciled with
the phrasing of the original focus group items generated
in each country. Back-translations were conducted
according to international standard translation proce-
dures [46].
Pilot testing
All previous focus group participants and subjects previ-
ously contacted but unable to attend the focus groups
were invited to the centers to participate in the initial
pilot test and cognitive debriefing exercise. Each country
included at least 24 children or adolescents but was free
to include additional subjects to ensure that a large
enough sample was available. The pilot test questionnaire
data were complemented by clinical, socio-demographic
and psychosocial data of the young patients and their par-
ents. A cognitive debriefing exercise followed the comple-
tion of the instrument by the participant families. In the
cognitive debriefing, children and adolescents were asked
to rate a subset of items regarding clarity and relevance
for young persons with dSS, importance to the individual
situation and if rewording could improve the item. A five-
point, Likert-type response scale was used with response
options of: not at all/never, slightly/seldom, moderately/
quite often, very/very often, extremely/always. The under-
standability of these response scale categories was also
assessed in the cognitive debriefing.
The results from the pilot test were analyzed with re-
gard to preliminary operating characteristics and psy-
chometric properties to guide further selection of items.
Preliminary analysis results were reviewed together with
the feedback from the cognitive debriefing, allowing the
researchers to make decisions regarding item retention
for the final field test version of the questionnaire.
Field test
In the field test the QoLISSY questionnaire was adminis-
tered to newly identified study participants meeting in-
clusion criteria. Additional measures were included inthe field test to identify potential determinants and com-
ponents of HrQoL as well as for construct validation
purposes. Among these was the KIDSCREEN-52, a gen-
eric HrQoL measure to estimate convergent validity
[45]. Subjects approached for and agreeing to the re-test
were sent a second mailing about two weeks later with
the aim to receive data from 50% of the sample to exam-
ine test- retest reliability.
The operating characteristics and psychometric prop-
erties of the field test instrument were analyzed at the
item and scale levels according to classical test theory
[47]. Specifically, items were individually inspected for
missing values, distribution characteristics (mean, SD,
skewness and kurtosis) and item difficulty. Principal
component factor analyses was conducted to explore the
dimensionality of the core HrQoL domains and the add-
itional determinant scales, as specified in the conceptual
model derived from focus group results. On the scale
level, analyses were conducted to evaluate the score dis-
tribution and the reliability of the scores (internal
consistency, retest and split-half reliability in terms of
intraclass correlation coefficients). Criterion validity of
the QoLISSY instrument was tested via correlations with
the generic KIDSCREEN instrument and via analysis of
known group differences regarding diagnosis, treatment
status and height.
Confirmatory factor analysis (CFA) was used to test
the dimensional structure of the QoLISSY questionnaire.
The models’ goodness of fit was assessed using the main
fit indexes: maximum-likelihood χ2 p-value and χ2/de-
grees of freedom, comparative fit index (CFI) and root
mean square error of approximation (RMSEA). The ref-
erence values of χ2/df ≤ 2, CFI ≥ .95 and RMSEA ≤ .06
were considered indicators of model´s good fit to the
data; and the reference values of χ2/df ≤ 5, CFI ≥ .80
and RMSEA ≤ .10 were considered the threshold for
assessing the model’s fit as acceptable. All statistical ana-
lysis analyses were performed using SPSS (IBM SPSS
Statistics V 18) as well as with specific programmes
which had been used in previous international HrQoL
projects [48].
Results below are presented to provide information on
the psychometric performance of the instrument and
not to identify differences in populations or evaluate the
impact of clinical characteristics on HrQoL, which would
require a different study design.
Results
The overall sample across phases of the instrument de-
velopment consisted of 446 children. Eighty-four chil-
dren were included in the focus groups and 94 children
in the pilot test phase. In the field test, 268 children
returned the questionnaire of which 124 additionally
completed and returned the retest questionnaire.
Table 1 Focus group and pilot test sample of children and
adolescents according to age, diagnosis and treatment
Age group Diagnosis Treatment status Focus groups Pilot test
8-12 yrs ISS treated 6 8
untreated 15 11
GHD treated 17 27
untreated 0 4
13-18 yrs ISS treated 15 9
untreated 13 18
GHD treated 17 16
untreated 1 3
Total 84 96
ISS: idiopathic short stature; GHD: growth hormone deficiency.
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ment status, age group and gender varied across coun-
tries with each contributing sufficient numbers to ensure
the representativeness of the sample in each country: 89
in France, 118 in Germany, 84 in Spain, 109 in Sweden
and 48 in UK.
Focus group results
A total of 84 patients, 38 children (8–12 years) and 46 ado-
lescents (13–18 years), with ISS and GHD were recruited
into 28 focus groups with an average 4 participants, specif-




3. Social comparison 
4. Social exclusion 
5. Stigma 
6. Juvenalisation 
7. Positive comparison 
8. Social support/acceptance 
9. Future 
Physical 
1. Limitation in daily activities 
2. Energy 
3. Clothing 
4. Recreational activities   
Treatment  
1. Expectations about treatment 
2. External influences  
3. Psychological effect  
4. Treatment administration 
5. Side effects 
6. Benefits of treatment  
Figure 1 Domains and sub-domains resulting from the focus groups.From the focus group discussions a total of over 4000
statements were identified and condensed. The state-
ments were organized into domains and sub-domains
(Figure 1). The statement list was reduced in an investi-
gators consensus meeting by removing repetitious and
ambiguous items. The most frequently expressed ideas
consistent across countries were retained as well as fre-
quently mentioned concepts within a country to ensure
the greatest degree of content validity.
The conceptual model specifies the three core do-
mains of HrQoL, (physical, emotional and social) as well
as potential mediators or determinants in terms of cop-
ing, beliefs, treatment and concerns regarding the future.
In addition, moderator variables such as age, gender,
family situation and socio-economic status were in-
cluded. This model conceptualizes HrQoL as an out-
come or dependent variable, which is related to the
child’s stature as an independent variable on the back-
ground moderators and describes how growth related
HrQoL is affected by clinical and psychosocial mediators
regulating the intensity of impact of dSS on HrQoL
(Figure 2).
Following the statement reduction process a total of
124 items were formulated and arranged into 7 scales for
child report. Individual items were constructed to include
both positive and negative wording though the predomin-
ant direction describes impairment. Scale level scores were 
             Emotion 
1. Self confidence 
2. Embarrassment 
3. Negative affect (angry/sad) 
4. Worry about height 
5. Bothered about height 
6. Feeling hurt 
7. Isolation 
8. Satisfaction with height   
Coping 
1. Acceptance 
2. Ignoring/blocking out 
3. Aggression/acting out 
4. Denial 
5. Seeking/receiving support 
Future 
1. Work 
2. Not being left out 
3. Better life 
4. Future partner 
Beliefs 
1. Belief/attitudes about height 
Figure 2 Conceptual model of the QoLISSY questionnaire.
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lar scale and standardized on a scale of 0 to 100 such that
higher scores reflected better quality of life.
Pilot test results
The pilot test was conducted on a convenience sample
of 94 children (48 children and 46 adolescents across
the European centers) and reflected the intended range
of age, gender and diagnosis (refer to Table 1).
Some items were discarded at this stage because par-
ticipants judged them negatively during the cognitive
debriefing, e.g. the items were not applicable for the par-
ticipants or were not easily understood. This information
was combined with the results of the item analyses and





Mean SD Skewness Kurtosis Relevanc
%
Physical 10 1-5 2.0 1.1 1.1 0.7 82.5
Social 20 1-5 2.3 1.0 0.8 2.5 85.9
Future 6 1-5 2.0 1.1 1.1 1.1 82.2
Emotion 16 1-5 2.2 1.1 0.9 0.7 88.3
Coping 22 1-5 2.5 1.2 0.5 −0.2 89.1
Beliefs 16 1-5 2.0 1.2 1.0 0.3 84.6
Treatment 34 1-5 2.4 1.2 0.7 1.1 86.7
Total 124
Scale descriptive data (first 6 columns), respondent feedback (%) on relevance, clari
rejected and moved (next 2 columns); number of items retained for field test (last c
was moved to parent version.psychometric indicators, the behaviour of items and do-
mains or scales was assessed and poorly performing
items were removed. This process was conducted in a
second consensus discussion, resulting in a refined list
of 53 candidate items across six of the originally seven
scales. The Future scale was removed as a component of
the children’s questionnaire and included as a domain in
the parent version (see Table 2).
Field test
A previously identified convenience sample of parents
with children meeting study inclusion criteria were
mailed the instrument. A total of 544 questionnaires
were sent out to families and 337 were returned to the








% % % N N N
94.6 75.6 9.2 2 −1 7
96.0 82.8 11.5 13 −1/+2 8
96.9 77.8 7.8 2 4* ___
97.6 86,6 13.8 7 −2/+2 9
96.0 86,2 7.9 11 −1 10
97.4 73.1 6.3 12 0 4
96.1 85.3 5.8 19 0 15
53
ty, importance and need to reword items (next 4 columns), number of items
olumn). Child and parent feedback combined (n=98 – 190) Domain “Future”
Table 3 Sociodemographic and clinical characteristics of children and adolescents in the field test sample by age group
Subject characteristics Total Age group Age group
8–12 yrs 13–18 yrs
N 268 100% 129 48.1% 139 51.9%
Gender Female 114 42.5% 60 52.6% 54 47.4%
Male 154 57.5% 69 44,8% 85 55,2%
Main diagnosis GHD 109 40.7% 40 36.7% 69 63.3%
ISS 159 59.3% 89 56.0% 70 44,0%
Treatment status Treated 142 53,0% 58 40,8% 84 59,2%
Untreated 126 47,0% 71 56.3% 55 43.7%
Height SDS 0 to −1.499 77 31.4% 31 40.3% 46 59.7%
N = 246 −1.50 to −2.499 115 46,9% 67 58.3% 48 41.7%
−2.50 and lower 53 21.6% 21 39.6% 32 60.4%
GHD: growth hormone deficiency; ISS: idiopathic short stature; SDS: standard deviation score.
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tionnaires as well as accounting for the fact that only par-
ents but not their children had responded, 268 returned
patient questionnaires were included in the analysis.
(n=129: 8–12 years; n=139: 12–18 years, Table 3). In
addition, 124 retest responses were received, representing
about 50% of the sample as planned. Inspection of item
performance resulted in discarding three items from the
child version, so that the field test version included
50 items. The results were evaluated for reliability
and validity, including criterion and construct validity.
Exploratory factor analysis was used both to identify
the scale structure and to support the scoring system of
the questionnaire. In line with the conceptual model,
items representing the core domains (physical, social
and emotional) were subject to a principal component
factor analysis, with three factors extracted. The first fac-
tor with an Eigenvalue of 10.62 explained 48.3% of the
variance, the second added 6.0% to the variance with an
Eigenvalue of 1.33 and the third another 4.6% with an
Eigenvalue of 1.03, all three contributed to a cumulative
59% of variance explained (full analysis for all items not
shown here). Conceptually, the three core scales formed
the QoLISSY-QoL total score, with the three domainsTable 4 Psychometric properties of the QoLISSY child self rep
Domain Descriptive statistics
N Items N Children Mean SD Skew
Physical 6 268 73.69 22.80 -.951
Social 8 268 72.94 22.93 -.787
Emotional 8 268 72.69 23.87 -.938
Coping 10 257 55.60 22.38 -.190
Beliefs 4 266 69.13 28.59 -.776
Treatment 14 152 55.12 21.06 -.125
QoLISSY total score 22 268 73.10 21.39 -.802
α: Cronbachs Alpha; ICC: intra class correlation coefficient.
N for treatment scale is low because domain was answered only by GH- treated pa(Coping, height-related Beliefs, Treatment) serving as
additional determinant modules.
The scale distribution characteristics from the overall
dataset suggest a relatively high level of HrQoL in the
respondents with mean scores in the low 70’s for the
core domains and total QoLISSY-QoL. The magnitude
of the variance (SD) indicates good variability across the
scales, and the low floor and ceiling effects as well as ac-
ceptable skewness and kurtosis suggest appropriate op-
erating characteristics (Table 4).
In terms of internal consistency, Cronbach’s α reliabil-
ity was 0.8 and above, with less than 10 items per scale.
Split-half reliability was slightly lower but still satisfac-
tory psychometrically (>.70) [47]. The test-retest reliabil-
ity, calculated from the retest of a sample of 124
children and adolescents in terms of the intraclass cor-
relation coefficient (ICC, last column in Table 4) was
satisfactory with the exception of the Coping scale.
Construct validity was assessed by confirmatory factor
analysis of the three core QoL scales and was subse-
quently repeated for the three mediator domains (not
reported here).
The factorial model of the patient-reported QoLISSY
core instrument, which comprises the physical, socialorted scale in the field test sample
Reliability
ness % Floor % Ceiling N α Split-half N ICC
0.4 12.3 263 .84 .83 120 .80
0.4 10.4 265 .87 .83 121 .80
1.1 10.1 259 .88 .88 121 .85
1.2 1.2 244 .82 .65 110 .56
3.8 21.1 263 .85 .85 117 .83
0.7 0.7 143 .87 .74 72 .73
0.4 4.9 251 .95 .92 120 .88
tients; QoLISSY total score is sum of Physical, Social and Emotional domains.
FTotal HrQoL
It hurts to be left out of things because of my 
height
Because of my height I have problems 
getting the clothes I like
My height is the only thing others notice 
about me
Because of my height I am treated differently
Because of my height I get laughed at or 
teased
Others mistake me for being younger than I 
am
I feel small around others my age
Being asked about my height at school 
bothers me
Because of my height I depend others
It bothers me that others my age can go on 
fairground rides and I can't
I have to look up at others my age when I 
talk to them
Because of my height I have more trouble 
reaching things than others my age
Because of my height I have problems 
everyday
My height prevents me from doing things 
that other children my age do
My height bothers me
Despite my height I feel comfortable with 
the way I am
I am sad because of my height
I am insecure because of my height
I am happy with my height
Because of my height I am shy
I am fed up with comments about my height
































Figure 3 Three domain core HrQoL model (Child and Adolescent self report).
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Table 5 QoLISSY child self reported scale score
intercorrelations (Person r)




Coping -.064 -.025 -.002
Beliefs .566** .556** .635** .023
Treatment .116 .050 .065 .280** -.141
QoLISSY
total score
.901** .946** .920** -.032 .638** .084
**. Correlation coefficient is significant at the 0.01 level.
QoLISSY total score is sum of Physical, Social and Emotional domains.
Table 7 QoLISSY child self-reported scales score: means,
standard deviations and group differences by diagnosis
Diagnosis
ISS GHD t df p
M SD M SD
Physical 69.28 23.82 80.12 19.62 4.07 266 <.001
Social 67.57 23.17 80.77 20.26 4.94 266 <.001
Emotional 68.37 24.75 78.98 21.08 3.66 266 <.001
Coping 55.20 21.47 56.21 23.78 .352 255 .725
Beliefs 63.71 28.56 76.95 26.88 3.81 264 <.001
Treatment 56.36 21.84 54.42 20.70 -.544 150 .587
QoLISSY total score 68.41 21.93 79.96 18.66 4.50 266 <.001
ISS: idiopathic short stature; GHD: growth hormone deficiency;
M: mean; SD, standard deviation; t: t-value; df: degrees of freedom.
QoLISSY total score is sum of Physical, Social and Emotional domains.
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http://www.hqlo.com/content/11/1/76and emotional domain and a total score of HrQoL, had
an acceptable fit, with Χ2 (206, n = 263) = 615.35, p <.05,
Χ2/df = 2.99, CFI = .88 and RMSEA = .087. All items
showed factorial validity, with significant factor loadings
(p < .001) and, except for one item of the social domain
and of the emotional domain, standardized regression
weights were above the threshold of .50 (Figure 3).
The QoLISSY instrument showed high inter-correlations
of the three cores QoL scales while the association with
the Coping subscale was lower (Table 5).
Criterion validity was examined in terms of convergent
validity using a generic measure and in terms of known
groups validity using participants clinical data.
The QoLISSY scale scores demonstrated significant, but
only moderate, correlations with the physical and psycho-
logical well-being dimensions of the KIDSCREEN-52.
These correlations support thematic agreement, but also
suggest that the two instruments may not be measuring
identical constructs (Table 6).
In terms of known group validity, significant differences
were found between ISS and GHD patients (Table 7) be-
tween untreated vs. GH-treated children (Table 8) and be-
tween degrees of SS (very short vs. less short children,







QoLISSY Physical .20** .25** .33** .5
Social .18** .29** .38** .5
Emotional .25* .37** .41** .5
Coping .16* .20** .09 .1
Beliefs .22** .31** .41** .4
Treatment .23** .20* -.01 .2
QoLISSY total
score
.23** .33** .41** .5
Correlation Coefficients, *Significant at p<0.05, **Significant at p<0.01.
QoLISSY total score is sum of Physical, Social and Emotional domains.characterized by significantly lower HrQoL than those in
the mid range (−1.5 to −2.49 SD, n = 116) or the taller pa-
tients in the upper range (0 to −1.49 SD, n = 77).
The operating characteristics and psychometric prop-
erties of the child version of the questionnaire in the
field test thus fulfilled internal consistency, split half and
retest reliability as well as content, construct and criter-
ion validity criteria.
Discussion
The current paper describes the development and test-
ing of an instrument to assess the HrQoL of children
and adolescents with dSS. By following guidelines for
patient-reported outcome instrument development and
in cooperation with clinical and methodological experts
in five countries, a comprehensive, methodologically
sound and practical instrument was developed, which can
be used for clinical research as well as a tool to evaluate
treatment benefits in a practice environment.
Conceptually, the development process was guided by
the need to address the diverse subjective concerns of
children and adolescents whose families seek consultationhild self-report scales with subscales of KIDSCREEN-52
KIDSCREEN-52
elf Autonomy Parents Financial Social Schooling Bullying
0** .25** .25** .30** .23** .21** .40**
1** .29** .29** .28** .28** .24** .51**
8** .34** .34** .30** .29** .29** .43**
5* .16* .17** .11 .23** .18** .10
7** .33** .31** .22** .24** .21** .32**
4** .11 .14 .08 .16* .12 .08
7** .32** .32** .32** .29** .27** .48**
Table 8 QoLISSY child self-reported scales scores: means,
standard deviations and differences in by growth hormone
treatment status
Treatment status
Treated Untreated t df p
M SD M SD
Physical 80.15 19.60 66.42 24.01 5.09 266 <.001
Social 80.14 20.63 64.82 22.76 5.74 266 <.001
Emotional 78.20 22.11 66.47 24.33 4.14 266 <.001
Coping 54.17 23.94 57.16 20.52 −1.07 255 .286
Beliefs 71.96 28.86 65.99 28.06 1.71 264 .089
QoLISSY total score 79.49 18.95 65.90 21.77 5.42 266 <.001
M: mean; SD: standard deviation; t: t-value; df: degrees of freedom.
QoLISSY total score is sum of Physical, Social and Emotional domains.
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http://www.hqlo.com/content/11/1/76and treatment related to short stature. The use of focus
groups across age ranges, diagnoses and countries was a
prerequisite for assuring a broad level of input and con-
tent saturation. Through the focus groups, it was possible
to identify the relevant concepts associated with HrQoL
for both child and adolescent age groups, also taking into
account gender, diagnosis, treatment status and degree of
short stature across countries.
Statements from the focus groups were instrumental
in identifying the relevant concepts for item generation
and in guiding the development of the conceptual
model. The cognitive debriefings added to the refine-
ment of the items and provided evidence in support of
the conceptual framework, particularly in the separation
of concepts salient to children as compared to their
parents. The preliminary evidence of content and
construct validity from the pilot testing phase suggested
that though nominal differences in performance and
linguistic interpretations were detected, the conceptual
framework, domains and items would show sufficient
robustness across languages in the field and retest phase.
It is noteworthy that the development of the QoLISSY
questionnaire was a simultaneous process conductedTable 9 QoLISSY child self reported scales score: means, standa
Degree of short stat
Upper group Mid group
0 to −1.49 SD 1.5 to −2.49 S
M SD M SD
Physical 86.68 13.34 70.62 23
Social 85.45 17.08 68.75 23
Emotional 84.65 17.08 68.61 24
Coping 53.65 25.19 55.02 23
Beliefs 76.92 26.48 68.08 29
Treatment 58.50 18.46 49.96 24
QoLISSY total score 85.59 13.90 69.33 21
M: mean; SD: standard deviation F: F-value; df: degrees of freedom; p: significance l
QoLISSY total score is sum of Physical, Social and Emotional domains.concurrently in five European countries. This aspect is
rather innovative, as is the targeted nature of the instru-
ment that focuses on both GHD and ISS, is available for
patients self report from 8 to 18 years of age (and, as will
be described in a separate paper, for parents) and speci-
fies not only indicators but also determinants of HrQoL.
All of this makes QoLISSY unique and differentiates it
from available HrQoL measures in short stature youth.
Although overall the acceptance of the instrument and
its psychometric performance during the development
process was positive, some limitations must be consid-
ered. A challenge of this study was to recruit across
countries a comparable number of subject families with
equivalent clinical characteristics, especially as it related
to diagnosis and treatment. Furthermore, responsiveness
of the instrument to differences in HrQoL according to
treatment cannot be inferred from the cross-sectional
data reported here, so that additional longitudinal re-
search is needed.
In Europe, children with ISS are rarely treated with
GH so that this group was underrepresented. Respond-
ent fatigue, particularly in the youngest cohort, was a
concern although anecdotal evidence suggests that it
was not a substantive problem. In addition, the children
were asked to answer a number of in-depths questions
regarding their height - related functioning and well-
being, especially those participating focus groups and in
the pilot with cognitive debriefing sessions. In the field
test, additional HrQoL instruments were included to
allow for construct validation, which increased the bur-
den for respondents even though the field test version of
the QoLISSY instrument is reasonably short.
The focus of the questionnaire is on the HrQoL im-
pact of short stature as an isolated physical characteristic
in a population seeking health-care. The intended use of
the questionnaire is within a medically defined popula-
tion which will allow interpretation of the results related
to clinical and psychosocial mediators as described inrd deviations and differences by degree of short stature
ure (SDS height)
Lower group F df p
D ≤ −2.5 SD
M SD
.35 58.02 22.72 31.81 244 <.001
.12 59.37 20.25 27.34 244 <.001
.44 61.02 22.12 20.95 244 <.001
.07 59.99 16.99 1.28 235 .279
.51 59.08 27.70 6.29 242 .002
.43 54.91 17.88 2.32 134 .102
.67 59.47 19.60 32.04 244 <.001
evel.
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http://www.hqlo.com/content/11/1/76the conceptual model included in Figure 2. This model
illustrates the complex nature of HrQoL measurement
in this area, in that a number of factors have to be taken
into consideration in relation to HrQoL measurement.
The QoLISSY questionnaire provides one, previously
missing, element in that investigation. The tabled results
from this study are limited in their generalizability due
to the nature of the sample, though the instrument
could be useful to assess the height impact on HrQoL in
other diagnoses. Further studies will be needed to iden-
tify differences in levels of well-being and functioning
according to treatment status, pubertal status, age and
gender. The current dataset provides a valuable oppor-
tunity to examine the contribution of psychosocial deter-
minants such as coping mechanisms, social support,
behavioural problems and parents’ own well-being to
child-reported HrQoL. In addition, cross cultural per-
formance of the instrument in terms of its equivalence
across language versions needs to be examined.
The European QoLISSY study is an example of interna-
tional cooperation in the development of patient-reported
outcomes in a rare but important health condition
impacting on the lives of children and their families. Cur-
rently, the QoLISSY instrument is available in five lan-
guages and additional validation work for other languages
and environments is ongoing. Access to the instrument
is provided through a manual available at production
costs [49].
Hopefully, this tool will also be used in descriptive
HrQoL studies to identify patient needs for care. Patient
needs derived from HrQoL screening may suggest treat-
ments for SS that do not only include GH substitution
but also psychological interventions. If applied in clinical
outcomes research, the QoLISSY instrument might also
be used to comparatively quantify the benefit of such
therapies in health economic evaluation and to monitor
their implementation in standard care.
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